Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Vamsidhar Velcheti, MD, on CodeBreaK 100: Update on Use of Sotorasib in NSCLC

Posted: Monday, June 7, 2021

Vamsidhar Velcheti, MD, of New York University, discusses the significance of the CodeBreaK 100 trial for patients with KRAS G12C–mutant non–small cell lung cancer, as well as the development of sotorasib in this patient population.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.